OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) announced today that the Company
will host a live conference call Thursday, December 17, at 8:30 AM
Eastern Time to discuss the Oncologic Drug Advisory Committee (ODAC)
panel’s review of the supplemental New Drug Application (sNDA) for use
of Tarceva® (erlotinib) as first-line maintenance therapy for patients
with advanced or metastatic non-small cell lung cancer whose cancer has
not progressed following first-line treatment with platinum-based
chemotherapy.
To access the live call or the seven-day archive via the Internet, log
on to www.osip.com.
Please connect to the Company’s website at least 15 minutes prior to the
conference call to ensure adequate time for any software download that
may be needed to access the webcast. Alternatively, please call
1-877-879-6174 (U.S.) or 1-719-325-4758 (international) to listen to the
call. The conference ID number for the live call is 7991541. Telephone
replay is available approximately two hours after the call through
December 31, 2009. To access the replay, please call 1-888-203-1112
(U.S.) or 1-719-457-0820 (international) and reference ID number 7991541.
About OSI Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicine and changing
lives" by discovering, developing and commercializing high-quality,
novel and differentiated targeted medicines designed to extend life and
improve the quality of life for patients with cancer and
diabetes/obesity. For additional information about OSI, please visit http://www.osip.com.
This news release contains forward-looking statements. These
statements are subject to known and unknown risks and uncertainties that
may cause actual future experience and results to differ materially from
the statements made.
Factors that might cause such a difference
include, among others, OSI's and its collaborators' abilities to
effectively market and sell Tarceva and to expand the approved
indications for Tarceva, OSI’s ability to protect its intellectual
property rights, safety concerns regarding Tarceva,
competition
to Tarceva and OSI’s drug candidates
from other biotechnology and
pharmaceutical companies, the completion of clinical trials, the
effects of FDA and other governmental regulation, including pricing
controls,
OSI's ability to successfully develop and commercialize
drug candidates, and other factors described in OSI Pharmaceuticals'
filings with the Securities and Exchange Commission.
